$TRAW - Interesting scenario on a dilutive timeline. | Reddit — r/pennystocks Ideas & AI Summary

AI Summary

A small-float biotech thesis on Traws Pharma's Ratutrelvir versus Paxlovid with January Phase 2 data as catalyst and dilution risk.

TRAW — LONG The author argues Traws Pharma's Ratutrelvir is a next-generation Paxlovid alternative with ritonavir-free once-daily dosing and favorable interim Phase 2 data. The upcoming full Phase 2 readout in January is a catalyst; if the press release is solid, the small-float biotech could rally, but the author plans to exit into any pre-release climb. The main stated risk is that the cash-poor company has used prior run-ups for financing, so any rally may be diluted immediately.

Ph2 full release is on schedule in January, with that small cap if PR is solid I see a rally, but will exit most of position if it climbs in anticipation.

Score 1

▶ Full Post Text

**$TRAW** : $1.31 

This post will be updated with any News. 

**Shares Float** : 6.7M

**Short Float** : 3%

**RSI** : 29

**RV** : 0.22 (under radar) 

**Insider Own** : 17%

**Inst Own** : 16% 

**Last Financing** : 🚩 (Dec-30- 24) :  https://www.prnewswire.com/news-releases/traws-pharma-inc-announces-financing-up-to-72-6-million-from-leading-healthcare-institutional-investors-to-advance-tivoxavir-marboxil-development-for-h5n1-bird-flu-to-approval-302340168.html

**$TRAW** : small float, watching this one for dips. Multiple drugs in pipeline. Ratutrelvir (Covid) & Tivoxavir marboxil (Oral influenza, H5N1), Narazaciclib oncology asset. 

**Company is running low on cash** and used run ups for financing before, so I’m expecting any run up to be diluted immediately to fund future projects  . 

The short story: 

**leading competitor** : **Paxlovid**  (Goliath): (nirmatrelvir/ritonavir, from Pfizer) remains the leading oral antiviral treatment for mild-to-moderate COVID-19 in high-risk patients as of January 2026. It holds significant market share, with notable sales ($427 million in Q2 2025 alone) and widespread use globally.

**$TRAW** :  small start up Biotech : **Ratutrelvir**(David) :  Explicitly positioned as a **next-generation alternative** to Paxlovid, with key potential advantages:

**Ritonavir-free**: Avoids Paxlovid's ritonavir component, which causes drug-drug interactions (contraindicated in many patients on common medications) and side effects like dysgeusia (bad taste).

**Once-daily dosing** (vs. Paxlovid's twice-daily).

___

**Interim Phase 2 data** :  Showed fewer adverse events, no observed viral rebounds (vs. some with Paxlovid), and efficacy in Paxlovid-ineligible patients.
- The Phase 2 program includes a head-to-head non-inferiority trial against Paxlovid.

**Dec - 17** : Interim data (only 37 patients) released (-37%  massive sell the news), showed favorable safety profile( lower adverse than Paxlovid(Major established company ), including activity in paxlovid ineligible patients. Followed by a massive sell off : https://finviz.com/news/255922/traws-pharma-reports-positive-interim-clinical-data-with-ratutrelvir-versus-paxlovid-shows-activity-in-paxlovid-ineligible-covid-19-patients

**Catalyst and Play** : Ph2 full release is on schedule in January, with that small cap if PR is solid I see a rally, but will exit most of position if it climbs in anticipation. NFA my cb here is 1.12 when it was shared earlier in discord. Always do your own DD.

$TRAW - Interesting scenario on a dilutive timeline.

▶ Full Post Text

Ideas

More from Reddit — r/pennystocks